Table 1.
Study population features
| Pt ID |
Age | MRONJ- related drugs | Duration (months) | Cumulative dose (mg) | Systemic disease | Local risk factors for MRONJ | MRONJ site | MRONJ stage (AAOMS) | MRONJ stage (SICMF - SIPMO) |
|---|---|---|---|---|---|---|---|---|---|
| #1 | 62 | Denosumab* | 30 | 300 | – | – | Maxilla | 2 | 1 |
| #2 | 88 | Denosumab* | 36 | 360 | Hypertension | Dental extraction | Mandible | 1 | 1 |
| #3 | 59 | Clodronate | 24 | 19,800 | Hypertension | Dental extraction | Mandible | 1 | 1 |
| #4 | 69 | Alendronate | 6 | 1680 | Arthrosis | Periodontal disease | Mandible | 2 | 1 |
| #5 | 83 | Denosumab* | 12 | 120 | Hypertension, diabetes | – | Mandible | 1 | 2 |
| #6 | 52 | Alendronate | 84 | 23,520 | – | Dental extraction | Mandible | 2 | 2 |
| #7 | 55 | Denosumab* | 24 | 240 | – | Periodontal disease | Maxilla | 1 | 2 |
| #8 | 52 | Denosumab* | 24 | 240 | – | – | Mandible | 1 | 2 |
| #9 | 67 | Oral ibandronate | 10 | 1500 | – | Dental extraction | Mandible | 2 | 2 |
| #10 | 58 | Denosumab* | 84 | 840 | – | Peri-implantitis | Mandible | 3 | 3 |
| #11 | 68 | Clodronate | 84 | 16,800 | – | – | Mandible | 3 | 3 |
| #12 | 72 | Alendronate | 18 | 5040 | Hypertension | Dental extraction | Maxilla | 3 | 3 |
| #13 | 69 | Alendronate | 52 | 14,560 | Hypertension | – | Maxilla | 3 | 3 |
| #14 | 81 | Denosumab* | 24 | 240 | Hypertension, diabetes | Dental extraction | Mandible | 2 | 2 |
| #15 | 78 | Denosumab* | 24 | 240 | Hypertension | Periodontal disease | Mandible | 1 | 2 |
*Denosumab: 60 mg s.c. every 6 months